ClinicalTrials.gg
WithdrawnNCT06236308Updated Mar 7, 2025

TTAX03 for the Treatment of Lumbosacral Facet Joint Pain

A Phase 1 interventional study of TTAX03 10mg and TTAX03 25mg in Facet Joint Pain, sponsored by BioTissue Holdings, Inc. Withdrawn. Open to participants aged 35 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by BioTissue Holdings, Inc · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Study was stopped due to reprioritization for active studies

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Study summary

This is a pilot study examining the safety and efficacy of a single intra-articular (IA) injection of TTAX03 per joint to relieve severe spinal facet joint (FJ) pain and improve function in subjects with facet joint pain (FJP) in the lumbosacral region. The design is randomized, double blinded, placebo controlled and dose-group sequential.

Read the detailed description

This is a Phase 1, randomized, placebo-controlled, double-blinded dose ranging study design with two dose escalation cohorts to be conducted at three sites in the USA. The primary objective is to examine the safety of FJ IA injections with the test article. The fundamental framework for the number of subjects and dose escalation decisions is modeled on the widely utilized phase 1 "3+3" dose escalation design.

A second objective is to examine the efficacy of two doses of TTAX03. The efficacy null hypothesis (HO) is that one administration of TTAX03, introduced into each of two or four joints (at one or two levels) by IA injection, will have no more benefit with respect to pain relief and improved function than an equal volume of placebo (sterile saline). The alternate hypothesis (HA) is that TTAX03 will provide a clinically meaningful reduction in pain and improvement in function compared to placebo.

An exploratory objective is to examine the potential benefit in terms of reduced need for narcotic pain relief, radiofrequency ablation, or surgical procedures for relief of LBP.

02

Conditions studied

  • Facet Joint Pain

Browse trials for

03

In context

Arthralgia

277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.

Browse Arthralgia studies →

Lead sponsor

BioTissue Holdings, Inc is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written
  2. Women of (those who are not premenarchal, not surgically sterilized [hysterectomy or bilateral oophorectomy], or not ) may participate in the study if they meet all of the following conditions:

    • they are not breast feeding
    • they have a negative serum pregnancy test at screening
    • they agree to undertake a serum pregnancy test at screening, at 3 months, and upon exiting the study
    • they do not intend to become pregnant during the study
    • they are using adequate methods and they agree to continue using those methods for the duration of the study

    Adequate birth control methods are defined as: hormonal-topical, oral, implantable or injectable contraceptives; mechanical-spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or, surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use an adequate birth control method as described above for the remainder of the study.

    NOTE: Women who have had a bilateral tubal ligation are not considered to have been surgically sterilized and must agree to the conditions as specified above.

    Post-menopausal is defined as no menstrual period for at least one year.

  3. ≥ 35 and ≤ 85 years of age
  4. \<40 kg/m2
  5. Clinical suspicion of painful OA of the facet joint(s) in 1 to 4 lumbosacral joints (within 1 - 2 levels) of greater than 3 months duration.
  6. Evidence of OA of the facet in the lumbosacral region on MRI or X-ray within 3 months (e.g., joint space narrowing, the presence of osteophytes and/or subchondral cysts, articular process hypertrophy, subchondral bone sclerosis, articular and subarticular erosions).
  7. NRS score for "worst pain in the past 24 hrs" ≥ 5, using the first NRS value collected in the screening period.
  8. History of having attempted a regimen of conservative care, including physical therapy for ≥ 3 months.
  9. Positive response to two diagnostic MBB, defined as ≥ 80% reduction in pain, at any time within 1 hour, assessed at 1 hour, as self-reported by the subject, following each diagnostic block.
  10. White blood count ≥ 4,500 /uL, (ANC) > 1,000 / uL, count ≥ 75,000 /uL, ≥ 10 g/dL
  11. Normal (PT) and partial thromboplastin time (PTT).
  12. (HbA1c) ≤ 8%
  13. Adequate hepatic function (/ALT ≤ 1.5 × , total ≤ 1.2 × ULN)
  14. Adequate renal function ( ≥ 60 mL/min/1.73 m2)
  15. Currently insufficient pain relief from acetaminophen, NSAIDs or other non-opioid analgesic medications.

Exclusion criteria

Exclusion Criteria:

  1. Lactation or pregnancy
  2. Cardiovascular instability as indicated by any of the following identified at screening and verified at least once during the initial screening visit: uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic >100 mm Hg), uncontrolled arrhythmia or unstable angina pectoris.
  3. Cognitive impairment, mental illness, neuroses or untreated depression that would preclude understanding or reliably completing the patient reported outcome measures
  4. History within the past 12 months of gastrointestinal bleeding, myocardial infarction, chronic renal failure, hepatic fibrosis, , or hospitalization other than for elective procedures
  5. Non-ambulatory, bedridden, or with active fibromyalgia or central pain syndrome
  6. Hypoesthesia, paresthesia, or allodynia in either foot or leg
  7. Facet OA pain involving more than two levels (i.e., > 4 FJs)
  8. Use of > 30 morphine milligram equivalents (MME) per day (see Study Guide)
  9. Score ≥ 21 on the Beck Depression Inventory (BDI)
  10. Allergy to any local anesthetic agents
  11. Any of the following conditions:

    1. Local (spine) or systemic infection
    2. Tumor in the spine
    3. Acute (\< 3 months duration) vertebral fracture

    e. Systemic inflammatory disorder f. Radicular syndrome g. Cauda equina syndrome h. Ankylosing spondylitis i. Any arthritis not considered osteoarthritis, such as reactive, rheumatoid, psoriatic or enteropathic arthritis j. History of other disease or Crohn's disease

  12. Progressive neurological condition such as Parkinson's, Alzheimer's, Lou Gehrig's disease, etc.
  13. Clinical characteristics suggestive of discogenic pain (i.e., chronic low back pain that subsides in supine position but aggravated after long-time sitting or standing, radicular pain)
  14. Radiologic evidence and radicular pain indicating symptomatic herniated disc
  15. Sacroiliac joint pain or symptomatic nerve root impingement (neurogenic claudication) related to spinal stenosis
  16. Evidence of dynamic listhesis, or fixed listhesis >10 mm accompanied by intermittent claudication or spinal stenosis
  17. injections within 1 month of screening if injected into the lumbar spine remote from the index facet joints, or within 3 months of screening if injected into the index facet joints, or radiofrequency ablation treatment at any level in the lumbar spine within 6 months of screening for similar symptoms
  18. Prior surgery at the involved levels, including "failed back syndrome"
  19. History of spinal osteonecrosis, osteoporotic fracture, fracture around the index facet joint(s) within the past 3 years, or pars interarticularis defect
  20. Compensable disability or work injury, ongoing or anticipated litigation related to back injury
  21. Sickle cell disease
  22. Erythrocyte sedimentation rate (ESR) >40mm/hr
  23. Use of systemic medications within past 6 months, including chronic systemic corticosteroids, chemotherapy, or history of organ transplant (kidney, heart, lung)
  24. Concurrent treatment, or treatment in the past 6 months, with any agent
  25. Severe concurrent illness which, in the view of the investigator, would interfere with this 12-month study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TTAX03 10mg

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. 10 mg of TTAX03 in a 0.5 mL solution of sterile, preservative-free 0.9% NaCl (saline).

    Biological: TTAX03 10mg

  • Experimental
    TTAX03 25mg

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. 25 mg TTAX03 in a 0.5 mL saline solution; or 0.5 mL of saline alone.

    Biological: TTAX03 25mg

  • Placebo comparator
    Saline Control

    0.5 mL of saline alone

    Biological: Placebo Comparator: Control Saline

Interventions

  • BiologicalTTAX03 10mg

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.

  • BiologicalTTAX03 25mg

    TTAX03 is a sterile, lyophilized and micronized particulate human AM and UC product manufactured using aseptic techniques followed by terminal sterilization by gamma-irradiation in compliance with Current Good Tissue Practices (CGTP) and Current Good Manufacturing Practices (CGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells.

  • BiologicalPlacebo Comparator: Control Saline

    2 mL Sterile, preservative free 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. Physical, functional and physiological responses to the intervention, as well as unanticipated events

    Proportion of subjects with developing or worsening abnormalities on focused motor, sensory and reflex neurological exams; - and - Changes from baseline in blood chemistries, hematology, serum immunoglobulins, urinalysis, and markers of inflammation

    Time frame: 12-weeks post baseline

Secondary outcomes

  1. NRS pain score

    \>/ 30% reduction in the NRS pain score

    Time frame: At the end of 12, 26, 39, and 52 weeks following treatment, compared to placebo

  2. PROMIS-29

    Improvement by \>/ 5 points on the PROMIS-29

    Time frame: At the end of 12, 26, 39, and 52 weeks following treatment, compared to placebo

  3. NRS pain score

    Change from baseline in NRS value

    Time frame: At the end of 1, 4, 8, and 12 weeks following treatment, compared to placebo

  4. PROMIS-29

    Change from baseline in PROMIS-29

    Time frame: At the end of 12, 26, 39 and 52 weeks, compared to placebo

  5. ODI score

    Change from baseline in ODI score

    Time frame: At the end of 12, 26, 39 and 52 weeks, compared to placebo

  6. PGIC

    Change from baseline in PGIC

    Time frame: At the end of 12, 26, 39 and 52 weeks, compared to placebo

Other outcomes

  1. Frequency and amount of narcotic use, radiofrequency ablation and surgical intervention

    Exploratory- To characterize the need for alternative treatment

    Time frame: Following treatment with TTAX03 or placebo after 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Jan 2025, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Feb 1, 2024
StartEst.
Jul 15, 2024
Primary completionEst.
Jan 31, 2025
CompletionActual
Mar 4, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06236308
Lead sponsor
BioTissue Holdings, Inc
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Jul 15, 2024 (estimated)
Primary completion
Jan 31, 2025 (estimated)
Completion
Mar 4, 2025
Last update
Mar 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTAX-03

Start the discussion